Azora Therapeutics Inc

Azora Therapeutics, Inc., formerly Adial Pharmaceuticals, Inc., is a biopharmaceutical company focused on developing treatments for serious inflammatory diseases. The Company is developing differentiated therapies for serious immune-mediated and inflammatory diseases. Its pipeline is AT177. AT177 is an investigational oral drug being developed for inflammatory bowel diseases, with an initial focus on ulcerative colitis. AT177 can deliver potent, colon-targeted Aryl-hydrocarbon Receptor (AhR) agonism directly to the site of disease. It is designed to capture the therapeutic benefits of AhR activation while minimizing systemic exposure. AT177's lead indication is in ulcerative colitis (UC), which is a chronic inflammatory disease of the colon and rectum. It is advancing AT177, a fully synthetic, patented, oral colon-targeted AhR agonist. The Aryl Hydrocarbon receptor (AhR) governs mucosal immunity and epithelial barrier integrity in the gut.